Hypofractionated whole-breast radiotherapy in large breast size patients: is it really a resolved issue?
Aged
Breast Neoplasms
/ pathology
Carcinoma, Ductal, Breast
/ pathology
Carcinoma, Intraductal, Noninfiltrating
/ pathology
Carcinoma, Lobular
/ pathology
Female
Follow-Up Studies
Humans
Neoplasm Recurrence, Local
/ pathology
Prognosis
Radiation Dose Hypofractionation
Radiation Injuries
/ etiology
Radiotherapy, Intensity-Modulated
/ adverse effects
3D Conformal Radiotherapy
Breast cancer
Hypofractionated radiotherapy
Large breast size
Late toxicity
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
03 Aug 2021
03 Aug 2021
Historique:
received:
20
05
2021
accepted:
05
07
2021
entrez:
3
8
2021
pubmed:
4
8
2021
medline:
4
1
2022
Statut:
epublish
Résumé
The purpose of this study was to evaluate the impact of breast size on acute and late side effects in breast cancer (BC) patients treated with hypofractionated radiotherapy (Hypo-RT). In this study we analyzed patients over 50 years with a diagnosis of early BC, candidate for Hypo-RT after conservative surgery. Acute and late skin toxicities were evaluated in accordance with the RTOG scale. Multivariable logistic analysis was performed using dosimetric/anatomical factors resulted associated with toxicity outcome in univariable analysis. Among patients treated between 2009 and 2015, 425 had at least 5 years of follow-up. At RT end, acute skin toxicity ≥ G2 and edema ≥ G2 occurred in 88 (20.7%) and 4 (0.9%) patients, respectively. The multivariable analysis showed association of skin toxicity with boost administration (p < 0.01), treated skin area (TSA) receiving more than 20 Gy (p = 0.027) and breast volume receiving 105% of the prescription dose (V105%) (p = 0.016), but not breast size. At 5 years after RT, fibrosis ≥ G1 occurred in 89 (20.9%) patients and edema ≥ G1 in 36 (8.5%) patients. Fibrosis resulted associated with breast volume ≥ 1000 cm
Identifiants
pubmed: 34342725
doi: 10.1007/s12032-021-01550-6
pii: 10.1007/s12032-021-01550-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107Informations de copyright
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet. 2011;378(9804):1707e16.
Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20.
doi: 10.1056/NEJMoa0906260
Bentzen SM, Agrawal RK, START Trialists’ Group, et al. The UK standardisation of breast radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9:331–41.
doi: 10.1016/S1470-2045(08)70077-9
Bentzen SM, Agrawal RK, START Trialists’ Group, et al. The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371:1098–107.
doi: 10.1016/S0140-6736(08)60348-7
Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast: executive summary of an American society for radiation oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018;8:145–52.
doi: 10.1016/j.prro.2018.01.012
Ratosa I, Chirilă ME, Steinacher M, et al. Hypofractionated radiation therapy for breast cancer: preferences amongst radiation oncologists in Europe—results from an international survey. Radiother Oncol. 2020;155:17–26. https://doi.org/10.1016/j.radonc.2020.10.008 (Online ahead of print).
doi: 10.1016/j.radonc.2020.10.008
pubmed: 33065187
Ratosa I, Jenko A, Oblak I. Breast size impact on adjuvant radiotherapy adverse effects and dose parameters in treatment planning. Radiol Oncol. 2018;52:233–44.
doi: 10.2478/raon-2018-0026
Moody AM, Mayles WP, Bliss JM, et al. The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity. Radiother Oncol. 1994;33:106–12.
doi: 10.1016/0167-8140(94)90063-9
Brierley JD, Paterson IC, Lallemand RC, Rostom RY. The influence of breast size on late radiation reaction following excision and radiotherapy for early breast cancer. Clin Oncol (R Coll Radiol). 1991;3:6–9.
doi: 10.1016/S0936-6555(05)81031-3
Gray JR, McCormick B, Cox L, Yahalom J. Primary breast irradiation in large-breasted or heavy women: analysis of cosmetic outcome. Int J Radiat Oncol Biol Phys. 1991;21:347–54.
doi: 10.1016/0360-3016(91)90781-X
Goffman TE, Glatstein E. Hypofractionation redux? J Clin Oncol. 2004;22:589–91.
doi: 10.1200/JCO.2004.07.174
Vicini FA, Sharpe M, Kestin L, et al. Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2002;54:1336–44.
doi: 10.1016/S0360-3016(02)03746-X
Michalski A, Atyeo J, Cox J, Rinks M, Morgia M, Lamoury G. A dosimetric comparison of 3D-CRT, IMRT, and static tomotherapy with a SIB for large and small breast volumes. Med Dosim. 2014;39:163–8.
doi: 10.1016/j.meddos.2013.12.003
Croog VJ, Wu AJ, McCormick B, Beal KP. Accelerated whole breast irradiation with intensity-modulated radiotherapy to the prone breast. Int J Radiat Oncol Biol Phys. 2009;73:88–93.
doi: 10.1016/j.ijrobp.2008.04.036
Pignol JP, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008;26:2085–92.
doi: 10.1200/JCO.2007.15.2488
Hong L, Hunt M, Chui C, et al. Intensity-modulated tangential beam irradiation of the intact breast. Int J Radiat Oncol Biol Phys. 1999;44:1155–64.
doi: 10.1016/S0360-3016(99)00132-7
Donovan E, Bleakley N, Denholm E, et al. Breast technology. Group randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radio-therapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. 2007;82:254–64.
doi: 10.1016/j.radonc.2006.12.008
Formenti SC, Gidea-Addeo D, Goldberg JK, et al. Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol. 2007;25:2236–42.
doi: 10.1200/JCO.2006.09.1041
Offersen BV, Alsner J, Nielsen HM, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial; the DBCG HYPO trial. J Clin Oncol. 2020;38(31):3615–25.
doi: 10.1200/JCO.20.01363
Offersen BV, Boersma LJ, Kirkove C, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early-stage breast cancer. Radiother Oncol. 2015;114(1):3e10.
doi: 10.1016/j.radonc.2014.11.030
Jones HA, Antonini N, Hart AA, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol. 2009;27(30):4939e47.
doi: 10.1200/JCO.2008.21.5764
Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373–9.
doi: 10.1016/S0895-4356(96)00236-3
Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87.
doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
Hickey BE, James ML, Lehman M, et al. Hypofractionated radiation therapy for early breast cancer. Cochrane Database Syst Rev. 2016. https://doi.org/10.1002/14651858 .
doi: 10.1002/14651858
pubmed: 27884041
pmcid: 6464536
Franco P, Bartoncini S, Martini S, Iorio GC, Richard U. Do hypofraction and large breast size reciprocally fit in breast cancer radiotherapy? Ann Transl Med. 2019;7(Suppl 3):S146. https://doi.org/10.21037/atm.2019.06.26 .
doi: 10.21037/atm.2019.06.26
pubmed: 31576353
pmcid: 6685881
Onal C, Sonmez A, Arslan G, Oymak E, Kotek A, Efe E, Sonmez S, Dolek Y. Dosimetric comparison of the field-in-field technique and tangential wedged beams for breast irradiation. Jpn J Radiol. 2012;30(3):218–26. https://doi.org/10.1007/s11604-011-0034-7 .
doi: 10.1007/s11604-011-0034-7
pubmed: 22183829
Hannan R, Thompson RF, Chen Y, et al. Hypofractionated whole-breast radiation therapy: does breast size matter? Int J Radiat Oncol Biol Phys. 2012;84:894–901.
doi: 10.1016/j.ijrobp.2012.01.093
Corbin KS, Dorn PL, Jain SK, et al. Hypofractionated radiotherapy does not increase scute toxicity in large-breasted women: results from a prospectively collected series. Am J Clin Oncol. 2014;37:322–6.
doi: 10.1097/COC.0b013e31827b45b7
Patel AK, Ling DC, Richman AH, et al. Hypofractionated whole-breast irradiation in large-breasted women—is there a dosimetric predictor for acute skin toxicities? Int J Radiat Oncol Biol Phys. 2019;103:71–7.
doi: 10.1016/j.ijrobp.2018.08.024
De Rose F, Fogliata A, Franceschini D, et al. Hypofractionated whole breast irradiation and simultaneous integrated boost in large-breasted patients: long-term toxicity and cosmesis. Clin Breast Cancer. 2020;20(6):527–33. https://doi.org/10.1016/j.clbc.2020.06.005 .
doi: 10.1016/j.clbc.2020.06.005
pubmed: 32665192
De Santis MC, Bonfantini F, Di Salvo F, et al. Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy. Breast. 2016;29:90–5. https://doi.org/10.1016/j.breast.2016.07.013 .
doi: 10.1016/j.breast.2016.07.013
pubmed: 27476083
La Rocca E, Meneghini E, Lozza L, et al. Older age and comorbidity in breast cancer: is RT alone the new therapeutic frontier? J Cancer Res Clin Oncol. 2020;146(7):1791–800. https://doi.org/10.1007/s00432-020-03243-5 .
doi: 10.1007/s00432-020-03243-5
pubmed: 32405744